Charmacy Pharmaceutical Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
Charmacy Pharmaceutical has been growing earnings at an average annual rate of 16.1%, while the Healthcare industry saw earnings growing at 11.2% annually. Revenues have been growing at an average rate of 4.9% per year. Charmacy Pharmaceutical's return on equity is 8.7%, and it has net margins of 1.2%.
Wichtige Informationen
16.1%
Wachstumsrate der Gewinne
16.1%
EPS-Wachstumsrate
| Healthcare Wachstum der Industrie | 11.3% |
| Wachstumsrate der Einnahmen | 4.9% |
| Eigenkapitalrendite | 8.7% |
| Netto-Marge | 1.2% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
There Could Be A Chance Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) CEO Will Have Their Compensation Increased
May 13
There's Reason For Concern Over Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) Massive 40% Price Jump
Apr 24Charmacy Pharmaceutical Co., Ltd. (HKG:2289) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Jan 19These 4 Measures Indicate That Charmacy Pharmaceutical (HKG:2289) Is Using Debt Reasonably Well
Oct 25If EPS Growth Is Important To You, Charmacy Pharmaceutical (HKG:2289) Presents An Opportunity
Sep 17Is Charmacy Pharmaceutical (HKG:2289) A Risky Investment?
May 02What Type Of Returns Would Charmacy Pharmaceutical's(HKG:2289) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?
Mar 15Are Dividend Investors Making A Mistake With Charmacy Pharmaceutical Co., Ltd. (HKG:2289)?
Feb 17We Wouldn't Rely On Charmacy Pharmaceutical's (HKG:2289) Statutory Earnings As A Guide
Jan 27Returns On Capital At Charmacy Pharmaceutical (HKG:2289) Paint An Interesting Picture
Jan 09What Charmacy Pharmaceutical Co., Ltd.'s (HKG:2289) ROE Can Tell Us
Dec 22
Reflecting on Charmacy Pharmaceutical's (HKG:2289) Share Price Returns Over The Last Three Years
Nov 29Aufschlüsselung der Einnahmen und Ausgaben
Wie Charmacy Pharmaceutical Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 4,482 | 52 | 176 | 0 |
| 31 Mar 24 | 4,443 | 52 | 173 | 0 |
| 31 Dec 23 | 4,404 | 51 | 171 | 0 |
| 30 Sep 23 | 4,480 | 74 | 173 | 0 |
| 30 Jun 23 | 4,557 | 96 | 175 | 0 |
| 31 Mar 23 | 4,366 | 93 | 170 | 0 |
| 31 Dec 22 | 4,175 | 90 | 165 | 0 |
| 30 Sep 22 | 3,931 | 54 | 159 | 0 |
| 30 Jun 22 | 3,688 | 18 | 153 | 0 |
| 31 Mar 22 | 3,741 | 20 | 152 | 0 |
| 31 Dec 21 | 3,794 | 23 | 152 | 0 |
| 30 Sep 21 | 3,959 | 29 | 153 | 0 |
| 30 Jun 21 | 4,124 | 36 | 154 | 0 |
| 31 Mar 21 | 4,058 | 38 | 149 | 0 |
| 31 Dec 20 | 3,992 | 41 | 143 | 0 |
| 30 Sep 20 | 3,819 | 35 | 137 | 0 |
| 30 Jun 20 | 3,645 | 29 | 130 | 0 |
| 31 Mar 20 | 3,569 | 34 | 129 | 0 |
| 31 Dec 19 | 3,493 | 40 | 128 | 0 |
| 30 Sep 19 | 3,557 | 41 | 127 | 0 |
| 30 Jun 19 | 3,621 | 42 | 125 | 0 |
| 31 Mar 19 | 3,778 | 44 | 128 | 0 |
| 31 Dec 18 | 3,935 | 45 | 130 | 0 |
| 30 Sep 18 | 4,075 | 46 | 129 | 0 |
| 30 Jun 18 | 4,214 | 47 | 128 | 0 |
| 31 Mar 18 | 4,155 | 46 | 124 | 0 |
| 31 Dec 17 | 4,096 | 45 | 120 | 0 |
| 30 Sep 17 | 3,946 | 54 | 112 | 0 |
| 30 Jun 17 | 3,796 | 63 | 104 | 0 |
| 31 Mar 17 | 3,733 | 60 | 98 | 0 |
| 31 Dec 16 | 3,670 | 56 | 93 | 0 |
| 30 Sep 16 | 3,605 | 47 | 88 | 0 |
| 30 Jun 16 | 3,540 | 38 | 83 | 0 |
| 31 Mar 16 | 3,468 | 32 | 82 | 0 |
| 31 Dec 15 | 3,397 | 26 | 81 | 0 |
| 30 Sep 15 | 3,299 | 31 | 82 | 0 |
| 30 Jun 15 | 3,200 | 35 | 83 | 0 |
| 31 Mar 15 | 3,107 | 36 | 78 | 0 |
| 31 Dec 14 | 3,014 | 36 | 73 | 0 |
| 31 Dec 13 | 2,401 | 22 | 59 | 0 |
Qualität der Erträge: 2289 has high quality earnings.
Wachsende Gewinnspanne: 2289's current net profit margins (1.2%) are lower than last year (2.1%).
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: 2289's earnings have grown by 16.1% per year over the past 5 years.
Beschleunigtes Wachstum: 2289's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Erträge im Vergleich zur Industrie: 2289 had negative earnings growth (-46.2%) over the past year, making it difficult to compare to the Healthcare industry average (-16.9%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: 2289's Return on Equity (8.7%) is considered low.